Discontinuation and non-publication rates of U.S. clinical trials for the pharmacologic treatment of type 2 diabetes mellitus: A cross-sectional analysis - 24/03/22
Doi : 10.1016/j.diabet.2021.101317
Conner Howard a, ⁎ 
, Nicholas B. Sajjadi a, Samuel Shepard a, Jourdan Waddell a, Stacy M. Chronister c, Matt Vassar a, b, Micah Hartwell a, b
, Nicholas B. Sajjadi a, Samuel Shepard a, Jourdan Waddell a, Stacy M. Chronister c, Matt Vassar a, b, Micah Hartwell a, b a Office of Medical Student Research, Oklahoma State University Center for Health Sciences, 1111 W 17th St., Tulsa, OK 74107, United States
b Department of Psychiatry and Behavioral Sciences, Oklahoma State University Center for Health Sciences, Tulsa, OK, United States
c Department of Medical Education, Oklahoma State University Center for Health Sciences, Tulsa, OK, United States
⁎Corresponding author.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Le texte complet de cet article est disponible en PDF.
Plan
© 2021
Elsevier Masson SAS. Tous droits réservés.
Vol 48 - N° 2
Article 101317- mars 2022 Retour au numéro
Article précédent
- Dapagliflozin reduces adiposity and increases adiponectin in patients with type 2 diabetes and atherosclerotic disease at short-term: An active-controlled randomised trial
- Ikaro Breder, Vaneza Lira W. Wolf, Alexandre A.S. Soares, Luiz Sergio F. de Carvalho, Sheila T. Kimura-Medorima, Riobaldo M. Cintra, Joaquim Barreto, Daniel B. Munhoz, Jessica S. Cunha, Isabella Bonilha, Otavio R. Coelho-Filho, Thiago Quinaglia, Wilson Nadruz, Gil Guerra-Junior, Elza Muscelli, Andrei C. Sposito, ADDENDA-BHS2 Trial Investigators
- Variable incidence of ketoacidosis in youth with type 1 diabetes onset during COVID-19 pandemic peaks in France
- Juliette Delpeut, Elisa Giani, Dalila Louet, Marc de Kerdanet, Carine Choleau, Jacques Beltrand, the AJD Study Group (see appendix on line)
Bienvenue sur EM-consulte, la référence des professionnels de santé.